Carboplatin/Cisplatin

Phase 2Small molecule

Shanghai Hengrui Pharmaceutical Co., Ltd.

Carboplatin/Cisplatin is one of 49 small molecule programs targeting Oligometastatic. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OligometastaticRecruiting

Lung CancerRecruiting

OligometastaticPhase 2

Recruiting

Lung CancerPhase 1

Recruiting

Competition

Competitive Landscape

206 competitors in Lung Cancer

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

33 2

Tagrisso

AstraZeneca

Phase 3

19 3

Beyfortus

BeiGene

Phase 3

10 4

Abraxane

Bristol-Myers Squibb

Phase 3

7 5

Alecensa

Roche

Phase 3

3 6

Zepzelca

Jazz Pharmaceuticals

Phase 3

2 7

Tarlatamab-Dznl

Amgen

Phase 3

2 8

Lynparza

AstraZeneca

Phase 3

2 9

DATROWAY

Daiichi Sankyo

Phase 3

2 10

Ilaris

Novartis

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Recruiting

Oligometastatic

NCT06177925

Q4 2026

Phase 1Recruiting

Lung Cancer

NCT07381829

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Mechanism of Response to IMFINZI Neoadjuvant Therapy in Non-small Cell Lung Cancer Patients Based on Multiple-omics Models

Unknown status·PPeking Union Medical College Hospital·Phase 1/2·NCT04646837·20 enrolled

Patients With Advanced Solid Tumors1 trial

A Study of SHR-1802 in Combination With Adebrelimab in Patients With Advanced Solid Tumors

Unknown status· Shanghai Hengrui Pharmaceutical Co., Ltd. logo

Shanghai Hengrui Pharmaceutical Co., Ltd.·Phase 1/2·NCT05794477·132 enrolled

Lung Cancer1 trial

A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung Cancer

Recruiting·HHC Biopharma Inc.·Phase 1·NCT07381829·328 enrolled

Oligometastatic1 trial

A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC

Recruiting·NNanfang Hospital, Southern Medical University·Phase 2·NCT06177925·62 enrolled

Nasopharyngeal Cancer1 trial

A Study of Gemcitabine and Cisplatin/Carboplatin Plus Erlotinib in Patients With Nasopharyngeal Cancer

Completed·UUniversity Health Network, Toronto·Phase 2·NCT00603915·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Carboplatin/Cisplatin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Carboplatin/Cisplatin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Carboplatin/Cisplatin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Hengrui Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Shanghai Hengrui Pharmaceutical Co., Ltd.

Carboplatin/Cisplatin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Patients With Advanced Solid Tumors1 trial

Lung Cancer1 trial

Oligometastatic1 trial

Nasopharyngeal Cancer1 trial

References

Drug Info

Quick Facts

Related News